Stock FLRY3 FLEURY S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Fleury S.A.

Equities

FLRY3

BRFLRYACNOR5

Healthcare Facilities & Services

Market Closed - Sao Paulo
Other stock markets
 04:07:52 2024-04-26 pm EDT 		5-day change 1st Jan Change
14.61 BRL +4.28% Intraday chart for Fleury S.A. +4.06% -19.01%
Mar. 08 Transcript : Fleury S.A., Q4 2023 Earnings Call, Mar 08, 2024
Mar. 07 Fleury S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 9,670 8,575 5,702 5,661 9,864 7,963 - -
Enterprise Value (EV) 1 10,452 9,476 7,854 5,661 13,181 11,402 10,630 11,410
P/E ratio 31.2 x 33.8 x 16.4 x 16.3 x 20.7 x 12.7 x 10.2 x 9.68 x
Yield 2.03% 2.7% 5.97% - - 2.34% 5.16% 1.85%
Capitalization / Revenue 3.33 x 2.89 x 1.47 x 1.27 x 1.52 x 1.02 x 0.95 x 0.9 x
EV / Revenue 3.6 x 3.19 x 2.03 x 1.27 x 2.04 x 1.46 x 1.27 x 1.29 x
EV / EBITDA 14.2 x 11.3 x 7.44 x 4.76 x 7.55 x 5.74 x 4.9 x 4.96 x
EV / FCF 29.1 x 20.6 x 13 x - 12.9 x 14.5 x 11.9 x 11.6 x
FCF Yield 3.44% 4.85% 7.71% - 7.78% 6.91% 8.38% 8.65%
Price to Book 5.5 x 4.9 x 3.09 x - 1.72 x 1.47 x 1.34 x -
Nbr of stocks (in thousands) 332,582 333,235 332,818 384,725 546,806 545,041 - -
Reference price 2 29.08 25.73 17.13 14.71 18.04 14.61 14.61 14.61
Announcement Date 2/20/20 2/25/21 3/17/22 3/16/23 3/7/24 - - -
1BRL in Million2BRL
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2,905 2,972 3,873 4,463 6,471 7,788 8,362 8,840
EBITDA 1 737.7 837.5 1,056 1,190 1,746 1,988 2,171 2,303
EBIT 1 560.2 478.7 667.3 735 915.9 1,221 1,404 1,514
Operating Margin 19.28% 16.11% 17.23% 16.47% 14.15% 15.68% 16.78% 17.12%
Earnings before Tax (EBT) 1 426.2 340.7 496.1 405.4 531.3 860.7 1,073 1,157
Net income 1 312.3 257 349.9 307.9 423.8 637.5 795.3 864.7
Net margin 10.75% 8.65% 9.04% 6.9% 6.55% 8.19% 9.51% 9.78%
EPS 2 0.9333 0.7619 1.048 0.9048 0.8700 1.150 1.436 1.510
Free Cash Flow 1 359.2 459.3 605.4 - 1,025 788 891 987
FCF margin 12.36% 15.46% 15.63% - 15.85% 10.12% 10.66% 11.16%
FCF Conversion (EBITDA) 48.69% 54.85% 57.33% - 58.75% 39.65% 41.05% 42.86%
FCF Conversion (Net income) 115.01% 178.75% 173.02% - 242% 123.61% 112.04% 114.14%
Dividend per Share 2 0.5905 0.6943 1.023 - - 0.3412 0.7544 0.2700
Announcement Date 2/20/20 2/25/21 3/17/22 3/16/23 3/7/24 - - -
1BRL in Million2BRL
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 1,029 1,018 1,090 1,112 1,147 1,115 1,237 1,660 1,870 1,704 1,906 1,962 2,005 1,845
EBITDA 1 300.7 262.2 326.6 298 332.4 232.7 345.8 363.6 506 530.2 515 494 542.9 404.7
EBIT 1 185.2 154.8 219.1 184.6 222.9 108.3 214.5 197.8 318 185.7 319.9 314.5 360.5 229.7
Operating Margin 18% 15.2% 20.1% 16.6% 19.44% 9.72% 17.34% 11.92% 17% 10.89% 16.78% 16.04% 17.98% 12.45%
Earnings before Tax (EBT) 1 136.3 99.4 153.5 98.23 123.5 30.12 - - - - 218.1 208.2 266.5 123.3
Net income 1 94.96 70.8 110.4 70.51 96.01 30.95 93.85 74.43 174.2 81.28 167.5 - - -
Net margin 9.23% 6.96% 10.13% 6.34% 8.37% 2.78% 7.59% 4.48% 9.32% 4.77% 8.79% - - -
EPS 2 0.2857 0.2095 0.3333 0.2127 0.2857 0.0730 0.2476 0.2400 0.3100 0.1600 0.2800 0.3000 0.3500 0.2100
Dividend per Share 2 - 0.8952 - - - - - - - - - 0.1480 - -
Announcement Date 10/28/21 3/17/22 5/5/22 8/4/22 11/3/22 3/16/23 5/4/23 8/3/23 11/9/23 3/7/24 - - - -
1BRL in Million2BRL
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 781 901 2,152 - 3,317 3,439 2,667 3,447
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.059 x 1.076 x 2.037 x - 1.9 x 1.73 x 1.228 x 1.497 x
Free Cash Flow 1 359 459 605 - 1,025 788 891 987
ROE (net income / shareholders' equity) 19.8% 14.6% 19.5% - 10.9% 11.2% 13.3% 14.6%
ROA (Net income/ Total Assets) 7.71% 4.84% 6.04% - 4.38% 5.5% 6.46% -
Assets 1 4,052 5,310 5,794 - 9,686 11,588 12,310 -
Book Value Per Share 2 5.290 5.260 5.540 - 10.50 9.930 10.90 -
Cash Flow per Share 2 2.180 1.930 3.050 - 2.970 2.360 - -
Capex 1 208 188 413 - 414 573 554 583
Capex / Sales 7.15% 6.32% 10.67% - 6.4% 7.36% 6.63% 6.59%
Announcement Date 2/20/20 2/25/21 3/17/22 3/16/23 3/7/24 - - -
1BRL in Million2BRL
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Fleury S.A.

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
14.61 BRL
Average target price
19.9 BRL
Spread / Average Target
+36.21%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

1st Jan change Capi.
FLEURY S.A. Stock Fleury S.A.
-19.01% 1.55B
SONIC HEALTHCARE LIMITED Stock Sonic Healthcare Limited
-17.89% 8.25B
RADNET, INC. Stock RadNet, Inc.
+39.20% 3.58B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD. Stock Guangzhou Kingmed Diagnostics Group Co., Ltd.
-39.11% 2.46B
SYNLAB AG Stock SYNLAB AG
-8.06% 2.46B
DR. LAL PATHLABS LIMITED Stock Dr. Lal PathLabs Limited
-7.35% 2.38B
NEOGENOMICS, INC. Stock NeoGenomics, Inc.
-12.61% 1.81B
DIAN DIAGNOSTICS GROUP CO.,LTD. Stock Dian Diagnostics Group Co.,Ltd.
-40.66% 1.21B
METROPOLIS HEALTHCARE LIMITED Stock Metropolis Healthcare Limited
+7.56% 1.11B
ADICON HOLDINGS LIMITED Stock Adicon Holdings Limited
-15.34% 1.03B
Medical & Diagnostic Laboratories
  1. Stock Market
  2. Equities
  3. FLRY3 Stock
  4. Financials Fleury S.A.